| 15.01 -0.28 (-1.83%) | 04-25 14:06 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 18.57 | 1-year : | 20.42 |
| Resists | First : | 15.9 | Second : | 17.48 |
| Pivot price | 14.79  |
|||
| Supports | First : | 13.34 | Second : | 11.09 |
| MAs | MA(5) : | 15.19 |
MA(20) : | 14.9 |
| MA(100) : | 12.37 |
MA(250) : | 8.76 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 62 |
D(3) : | 63.2 |
| RSI | RSI(14): 49.7 |
|||
| 52-week | High : | 20.89 | Low : | 4.59 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ YMAB ] has closed below upper band by 34.9%. Bollinger Bands are 49.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 15.47 - 15.55 | 15.55 - 15.61 |
| Low: | 14.84 - 14.92 | 14.92 - 14.98 |
| Close: | 15.16 - 15.3 | 15.3 - 15.4 |
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
Tue, 23 Apr 2024
Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Up 7% - MarketBeat
Thu, 04 Apr 2024
Y-mAbs Therapeutics Insiders Who Sold Avert US$91m Market Cap Dip - Simply Wall St
Wed, 20 Mar 2024
YmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains? - Yahoo Finance
Thu, 14 Mar 2024
Y-Mabs Therapeutics CFO Resigns, Ensures Smooth Transition - TipRanks.com - TipRanks
Thu, 14 Mar 2024
Y-mAbs CFO Bo Kruse resigns, search for successor begins - Investing.com
Fri, 01 Mar 2024
Y-mAbs Therapeutics, Inc. (YMAB) Q4 2023 Earnings Call Transcript - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 44 (M) |
| Shares Float | 25 (M) |
| Held by Insiders | 14.5 (%) |
| Held by Institutions | 66.2 (%) |
| Shares Short | 2,240 (K) |
| Shares Short P.Month | 2,170 (K) |
| EPS | -0.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.3 |
| Profit Margin | -25.3 % |
| Operating Margin | -13.7 % |
| Return on Assets (ttm) | -9.9 % |
| Return on Equity (ttm) | -20.4 % |
| Qtrly Rev. Growth | -25.8 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.93 |
| EBITDA (p.s.) | -0.47 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -27 (M) |
| Levered Free Cash Flow | -14 (M) |
| PE Ratio | -30.76 |
| PEG Ratio | 0.3 |
| Price to Book value | 6.52 |
| Price to Sales | 7.77 |
| Price to Cash Flow | -24.23 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|